Concurrent genetic and standard screening test for hearing reduction

Marina Davcheva Chakar, Gjorgji Bozhinovski, Emilija Shukarova Stefanovska, Dejan Trajkov

1. University Clinic of Otorhinolaryngology, Faculty of Medicine, Ss. Cyril and Methodius University, Vodnjanska 17, 1000 Skopje, Republic of North Macedonia
2. Research Centre for Genetic Engineering and Biotechnology “Georgi D. Efremov”, Macedonian Academy of Science and Art, Boulevard Krste Petkov Misirkov, 1000 Skopje, Republic of North Macedonia
3. Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University, 50. Divizija 6a, 1000 Skopje, Republic of North Macedonia

Received: November 2020; Accepted: December 2020

Abstract

Reduction of hearing is the most common sensory impairment among newborns with an incidence of 1-3 per 1000 births. Introduction of an Auditory Newborn screening program allows early identification of hearing impairment. Mainly, congenital hearing loss in early childhood is a result of genetic changes. Due to high frequency of GJB2 pathogenic variants, its molecular characterization among sensorineural hearing reduction cases is already conducted as a routine analysis in many countries. The aim of this study is to show our initial results in the effort to determine whether genetic screening along with the standard hearing screening in newborns is justified. Otoacoustic emission (OAE) method was conducted in 223 newborns at risk of hearing impairment. Among them, 7 did not pass the test in both ears while 9 exhibited one-sided hearing loss. In all 7 children with indication of profound bilateral deafness, the diagnosis was confirmed using auditory brainstem response. Genetic screening of GJB2 gene was performed in 6 of them. Genetic analysis of GJB2 revealed homozygous state of the most common pathogenic variant 35delG in 3 (50%) of the analyzed infants. In the remaining 3 no pathogenic variant was determined. The results indicate that performing auditory OAE together with genetic screening is justified. In newborns who have not passed the hearing screening test and have profound hearing loss, without other syndrome traits, screening for mutations of GJB2 gene should be conducted. Genetic screening enables establishment of early definite diagnosis for deafness and helps in conducting adequate therapy providing timely rehabilitation and social inclusion of deaf child.

Keywords: hearing loss, genetic screening, auditory screening, GJB2 gene

Introduction

Deafness or profound hearing loss is one of the most common congenital abnormalities and presents a huge public health problem. In 1999, following the introduction of hearing screening in newborns, the American Academy of Pediatrics reported that bilateral hearing loss was found in 1-3 per 1000 newborns and in 2-4 per 1000 newborns in the intensive care units (Erenberg et al., 1999). Data from the newborn screening programs in Island, Colorado and Texas have shown that
2–4 per 1000 newborns have hearing loss (Downs, 1995; Finitzo et al., 1998; Vohr et al., 1998). In another retrospective study, hearing loss was found in 1 per 811 newborns without risk factors and in 1 of 75 newborns with risk factors for hearing loss (Connolly et al., 2005). Successive introduction of the program for universal auditory screening in many countries continually changes the data on prevalence of hearing loss in newborns.

Hearing impairment is a highly heterogeneous condition caused by either environmental or genetic factors. In developed countries hearing impairment due to environmental factors is reduced, mainly due to improved medical care during pregnancy and early childhood. In as many as 50% of congenitally deaf children, deafness is of genetic nature.

In the etiology of hearing impairment there is also a high genetic heterogeneity. In the last two decades over 110 chromosome loci and more than 65 genes responsible for hearing loss have been identified (http://hereditaryhearingloss.org, accessed November 6, 2020).

About 70% of cases of genetic deafness are non-syndromic; deafness is the unique clinical manifestation. Non-syndromic hearing loss is further categorized according to the pattern of inheritance. Of all non-syndromic hearing impairments, autosomal recessive inheritance has been found in 70-80%, in the remaining 15-20% autosomal dominant inheritance has been described, in 5% it has been linked with X-chromosome, and in 1% due to mitochondrial gene changes (Petersen and Willems, 2006). Beside the extreme genetic heterogeneity, pathogenic variants in one gene, Gap junction beta-2 protein (GJB2), located at DFNB1 locus (13q12.11) are the major cause of autosomal non-syndromic hearing loss (Apps et al., 2007). GJB2 gene encodes synthesis of connexin 26, protein belonging to the family of membrane proteins that is involved in forming ion channels-connexons, allowing intercellular transport of ions and small molecules.

GJB2 is a small gene with a length of about 5.5 kilobases, with two exons, of which only one contains the coding sequence. The most common defect in this gene is a deletion of guanine (G) in a sequence of six Gs extending from position 30–35 of Cd26 cDNA – (35delG) leading to premature termination of the connexin 26 protein synthesis due to formation of stop codon (Denoyelle et al., 1997). The frequency of this mutation differs among different populations, and shows a large variability in its clinical impact on the hearing impairment. The 35delG mutation is frequently detected in Caucasian populations (Europe and North America). It is more common in the Mediterranean countries (2.5–4%), whereas its incidence in the North European countries declines to 1.3% (Zelante et al., 1997). In addition, more than a hundred different pathogenic variants have also been discovered within this gene, some of them found only once, while some of them appear very frequently among patients with non-syndromic deafness in different ethnic groups (Kennenson et al., 2002).

As a result of the high frequency of GJB2 mutations, determination of spot mutations in this gene in non-syndromic deafness is conducted as a routine analysis in many countries. The rate of carriers of recessive deafness in the general population, which is associated with GJB2 mutations, is approximately 1 in 33 (Chan and Chang, 2014).

The pattern of inheritance is an autosomal recessive and when present in homozygote state it almost always causes a prelingual, profound deafness (Phillips et al., 2013). In terms of phenotypic traits GJB2 hearing deafness is bilateral, symmetrical and profound to complete deafness (Cryns et al., 2004; Denoyelle et al., 1999). The vestibular function is usually not affected (Denoyelle et al., 1999).

The aim of this study was to determine whether use of genetic screening along with standard hearing screening in newborns is justified.

Case reports

In the period between 2016 and 2017 hearing screening with the method of otoacoustic emission (OAE) was conducted in 223 newborns at the Audiology Department of the University Clinic for Ear, Nose and Throat, Vodnjanska 17, 1000 Skopje, Republic of North Macedonia. A total of 213 (95.5%) children from this group were with risk factors for hearing impairment (ototoxic medications, premature birth, low birth weight and intensive care longer than 7 days) and the remaining 10 (4.5%) children without risk factors for hearing loss were referred for audiological evaluation due to poor reaction to sound stimuli or poorly developed speaking skills without risk factors for hearing reduction. Of the total of 223 children, 207 (93%) passed the screening test, 7 (3%) newborns failed the test in both ears, and 9 (4%) newborns passed the test in one ear. In all 7 children who did not pass the OAE, hearing testing with the Auditory Brainstem Response (ABR) method was done and a profound sensorineural hearing impairment was found in both ears. Genetic screening for pathogenic variants in GJB2 gene was conducted in six cases at the Research Centre for Genetic Engineering and Biotechnology “Georgi D. Efremov”, Macedonian Academy of Sciences and Arts. Direct sequencing of the coding exon 2 of the GJB2 gene was performed using BigDye Terminator v1.1 kit on ABI Prism 3130 Genetic analyzer (Thermo Fisher Sci., USA). The parents of one of these newborns refused to make the test. A written parental informed consent for genetic testing was obtained. In this paper we will present only three cases with 35delG pathogenic variant of the GJB2 gene on both chromosomes. The evaluation of every case included family history, physical examination consisting of otologic examination, airway examination,
standard screening test for hearing, ABR, neurological examination, magnetic resonance imaging (MRI) of temporal bone and genetic test for GJB2 pathogenic variants.

Case 1. Patient A.J.

A two-month-old infant was brought to the Audiology Department due to poor response to sound stimuli. The parents’ anamnesis revealed no reaction to the mother’s voice, while sharp sound scared the baby. Familial history showed no deaf or hard of hearing members in the family. The baby was of Caucasian origin. Syndromic features were absent. The infant failed the OAE screening in both ears. ABR examination using click stimuli for frequency range of 0.5, 1, 2 and 4 kHz showed auditory responses at 80 db intensity only. Neurologic examination and CNS ultrasound evaluation were within normal range. A MRI of temporal bone was conducted as a part of etiologic diagnosis of hearing loss revealing normal temporal bone anatomy of both ears. Genetic analysis revealed presence of the 35delG pathogenic variant of the GJB2 gene on both chromosomes. Soon after the established diagnosis the child was fit with amplifications. The patient underwent a cochlear implantation at the age of 9 months.

Case 2. Patient D.P.

A three-month-old baby was brought to our department due to poor response to sound stimuli. The parents’ anamnesis revealed that the baby reacted to sound stimuli until the age of 5.5 months, but it stopped reacting after receiving regular vaccine. Family history revealed no other members with hearing loss. Syndromic features were absent. We performed screening OAE test and ABR. The baby failed the hearing screening. ABR examination using click stimuli for frequency range of 0.5, 1, 2 and 4 kHz showed profound deafness; auditory responses were absent at 90db intensity in both ears. MRI revealed normal temporal bone in both ears. Neurological and ENG results were in normal limits. The 35delG pathogenic variant of the GJB2 gene was determined in a homozygous state. After three-month hearing aid trial, the infant received cochlear implant.

Case 3. Patient M.S.

A three-year-old child was brought to the Audiology Department due to poorly developed speaking skills. Family history revealed no other members with hearing loss. Syndromic features were absent. The child failed the hearing screening. ABR examination using click stimuli for frequency range of 0.5, 1, 2 and 4 kHz showed profound deafness; auditory response at 90db intensity in both ears. The MRI revealed normal temporal bone in both ears. MRI of temporal bone was conducted revealing normal temporal bone anatomy of both ears. Neurological examination was in the normal range. The 35delG pathogenic variant of the GJB2 gene was determined in a homozygous state. The child received cochlear implant after three months of establishing the diagnosis.

The intervention in all these cases has been provided in an auditory-verbal setting with improved speech and language skills.

Discussion

35delG pathogenic variant of the GJB2 gene is found in a high percentage among NSHL cases of many countries in north, south and central Europe (28-68%). The ethnicity of patients is an important variable. The 35delG mutation accounts for up to 63% of the mutant alleles in Caucasians (Gasparini et al., 2000). A high prevalence of 35delG (67.49%) and W24* (23.01%) mutations in the GJB2 gene has been determined in patients (Caucasians and Gypsies, respectively) with non-syndromic inherited deafness in the Republic of Macedonia (Sukarova Stefanovska et al., 2012; Sukarova Stefanovska et al., 2017). Determination of the high prevalence of these two pathogenic variants in GJB2 gene among deaf persons in our Country make the clinician more confident while choosing a test for genetic screening in children who have failed the screening hearing loss test, with profound hearing loss and hearing loss of unknown etiology.

In three children (50%) included in this study, who did not pass the hearing test and who were diagnosed with profound hearing loss, the genetic analysis of GJB2 gene mutations showed bi-allelic 35delG mutation. The results obtained in this study imply the need of genetic testing for GJB2 gene mutations in all children with hearing loss of unknown etiology in line with the recommendations given by other authors (Alford et al., 2014; Kenna et al., 2007).

It is noteworthy to mention that no risk factors at birth were present in any of these children. According to literature data 50% of children with congenital deafness have no risk factors at birth, and hence a universal newborn hearing screening was introduced in the developed countries many years ago (Alford et al., 2014). Our results indicate the need of implementation of universally accepted hearing screening of newborns in the Republic of North Macedonia.

All three presented cases had a profound hearing loss. These findings correspond with the results obtained in other studies indicating a significant association between genotype of GJB2 gene and the degree of hearing loss (Cryns et al., 2004). Since this condition is recessive, the bi-allelic GJB2 variant in these patients has confirmed the etiology of hearing impairment and helped in timely intervention and auditory speech rehabilitation therapy in these children.

The remaining 3 (50%) children, who underwent analysis of the gene for connexin 26 synthesis, showed no mutation in the gene GJB2 at both chromosomes. The
cause for hearing impairment in these children was not GJB2 pathogenic variant, but we did not exclude the possibility of other unknown or unexamined genetic causes for hearing loss.

The high prevalence of 35delG among patients of the examined group implies the need of genetic screening of GJB2 gene pathogenic variants among newborns who have not passed the auditory screening and who have deafness of unknown etiology.

One of our examined children who failed the auditory screening had a bilateral hearing loss and the biallelic GJB2 gene mutation, and was three years old. Unfortunately, there are still cases with severe sensorineural hearing loss that are being diagnosed in older age. There are many reasons responsible for this situation, including not sufficient information and education of parents and above all, lack of universally accepted newborn standard hearing screening in the Republic of North Macedonia.

The results of this study have proved that genetic screening along with newborn hearing screening provide better early identification of hearing deficits and rapid therapeutic intervention. Our results correspond with the results from other studies (Sun et al., 2015; Zhang et al., 2013). Cochlear implantation (CI) is the most important and effective treatment in patients with profound sensorineural hearing loss. All three cases presented in this study, with profound hearing loss and bi-allelic 35delG pathogenic variant, underwent CI. The intervention in these cases was provided in an auditory-verbal setting with improved speech and language skills. The results are similar to our earlier reported data and are in agreement with the literature revealing that patients with genetic causes hearing loss etiology show good CI speech perception outcomes (Davcheva Chakar et al., 2014; Nishio et al., 2017; Paludetti et al., 2012).

Conclusion

The high frequency of 35delG mutation among patients in this study warrants screening for this mutation among infants who did not pass the hearing screening. The results of our study prove that it is beneficial to use genetic screening along with neonatal hearing screening in order to improve early identification of hearing loss and to reach an early decision for cochlear implantation. Therefore, basic scientific knowledge about inherited deafness will be transferred from the laboratory to the patient’s bed and will render appropriate medical evaluation and treatment of patients with hearing loss.

References


Connolly, J.L., Carron, J.D., Roark, S.D., 2005. Universal newborn hearing screening: are we achieving the Joint Committee on Infant Hearing (JCIH) objectives? Laryngoscope 115(2), 232-236. Available at: https://doi.org/10.1097/01.mlg.0000145724.00787.49.


Maced. pharm. bull., 66 (2) 35 – 40 (2020)
Concurrent genetic and standard screening test for hearing reduction


Резиме

Истовремено спроведување на генетски и стандарден тест при скрининг кај новородени со редукција на слухот

Марина Давчева Чакар¹, Ѓорѓи Божиновски², Емилија Шукаровска Стефанова², Дејан Трајков³*

¹Универзитетска клиника за оториноларингологија, Медицински факултет, Универзитет ,,Св. Кирил и Методиј“, Водњанска 17, 1000 Скопје, Република Северна Македонија
²Истражувачки центар за генетско инжењерство и биотехнологија ,,Ѓорѓи Д. Ефремов”, Македонска академија на науки и уметности, Булевар Крсте Петков Мисирков, 1000 Скопје, Република Северна Македонија
³Институт за имунобиологија и хума генетика, Медицински факултет, Универзитет ,,Св. Кирил и Методиј“, 50 Дивизија ба, 1000 Скопје, Република Северна Македонија

Ключни зборови: редукција на слух, генетски скрининг, аудиторен скрининг, GJB2 ген

Намалување на слухот е најчестото сензорно оштетување кај новороденињата со инциденца од 1-3 на 1000 рагања. Воведување на програма за аудитивен скрининг на новородениња овозможува рано идентификување на оштетувањето на слухот. Главно, вроденото губење на слухот во рано детство е резултат на генетски промени. Поради големата фреквенција на патогени варијанти на GJB2 меѓу новородените со сензоринеурална редукција на слухот, во многу земји неговата молекуларна карактеризација веќе се спроведува како рутинска анализа. Целта на овој труд е да ги прикажеме нашите почетни резултати во напорот да утврдиме дали е оправдана употребата на генетскиот скрининг заедно со стандардниот скрининг за слух кај новороденињата. Методата на отокустична емисија (ОАЕ) беше спроведена кај 223 новороденчиња со ризик од оштетување на слухот. Меѓу нив, 7 не го поминаа тестот на двете уши, додека 9 покажаа постоење на еднострано губење на слухот. Кај сите 7 деца со индикација за постоење на тешка билатерална глувост, дијагнозата е потврдена со методата на аудитиви одговори на мозочното стебло. Генетскиот скрининг на генот GJB2 е извршен кај 6 од нив.  Генетската анализа на GJB2 открива присуство на хомозиготна форма на најчестата патогена варијанта 35delG кај 3 (50%) од анализираните новороденчиња. Во преостанатите 3 не е утврдено постоење на оваа форма. Резултатите укажуваат дека е оправдано спроведување на аудитивни ОАЕ заедно со генетскиот скрининг. Кај новороденињата кои не го поминале скрининг тестот и имаат тешка редукција на слухот, без други карактеристики на синдромска наглувост, треба да се спроведе скрининг за мутации на генот GJB2. Генетскиот скрининг овозможува воспоставување на рана дефинитивна дијагноза за глувост и помага при спроведување на соодветна терапија која обезбедува навремена рехабилитација и социјална рехабилитација на глувите.